About Eikon
Eikon is a publicly listed company based in Hayward (United States) founded in 2019 by Robert Tjian, Luke Lavis, Eric Betzig, and Xavier Darzacq. Protein dynamics are tracked and measured for drug discovery processes. Eikon has raised $1.16 billion across 4 funding rounds from investors including ARE, T. Rowe Price and StepStone Group. The company has 431 employees. Eikon was last valued at $908.2 million in February 2026. Its chief executive, as recorded, is Roger M Perlmutter. Its website eikontx.com draws about 13 thousand monthly visits. Eikon offers products and services including Therapeutic Platform, Pipeline, and Eikon Systems. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its competitors include Biogen, ADMA Biologics and Kymeratx; 3 of its 3 listed competitors have raised funding.
Company details
Eikon was founded in 2019 and is headquartered in Hayward, United States. The company operates in the biotechnology sector, focusing on drug discovery through a therapeutic platform. Protein dynamics are analyzed by researchers using live-cell super-resolution microscopy integrated with computing and engineering technologies. This approach supports the identification and evaluation of potential drug targets.
- Headquarters Hayward, United States
- Employees 431
- Founders Robert Tjian, Luke Lavis, Eric Betzig, Xavier Darzacq
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website eikontx.com
- Social LinkedIn X
- Legal Name Eikon Therapeutics, Inc.
- Net Profit-$324.25 M (USD)as on Dec 31, 2025
- EBITDA-$324.25 M (USD)as on Dec 31, 2025
- Total Equity Funding$1.16B (USD)
in 4 rounds
- Latest Funding Round$350.7M (USD), Series D
Feb 2025
- InvestorsARE
& 23 more
- Employee Count431
Products & Services of Eikon
Eikon offers a comprehensive portfolio of products and services, including Therapeutic Platform, Pipeline, and Eikon Systems.
Platform for developing and managing therapeutic products
System for advancing therapeutic drug pipelines
Systems for reporting and handling product safety concerns
Funding Insights of Eikon
Eikon has successfully raised a total of $1.16B across 4 strategic funding rounds. The most recent funding activity was a Series D round of $350.7 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.16B
- Total Rounds 4
- Last Round Series D — $350.7M
- First Round $148M
(May 2021)
- Investors Count 24
All 4 funding rounds of Eikon with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2025 | $350.7M | Series D | – | – | |
| Jun 2023 | $140.76M | Series C | – | – | – |
| Jan 2022 | $517.8M | Series B | – | T. Rowe Price, CPP Investments | – |
| May 2021 | $148M | Series A | – | TCG |
| Date | Valuation | Stage |
|---|
Full valuation and stage history of Eikon
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $908.2M (Feb 2026). 24 investors in total: 24 institutional.
Investors in Eikon
Eikon has secured backing from 24 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, T. Rowe Price and StepStone Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Seed and early-stage technology companies are funded by Lux Capital. | luxcapital.com | Menlo Park, United States | ||
AME Cloud Ventures is focused on investing in data-driven technology companies. | amecloudventures.com | Palo Alto, United States | ||
Early-stage investments in US life science startups are focused on. | 2007 | thecolumngroup.com | San Francisco, United States | |
| e15vc.com | ||||
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
Investment and transformation services for entrepreneurs in technology and finance sectors. | generalcatalyst.com | Cambridge, United States | ||
Diversified asset management firm and private fund focused on debt, equity, and secondary market investments in multiple sectors | 2007 | stepstonegroup.com | New York, United States | |
Capital is managed across multiple sectors for a single family. | soroscap.com | New York, United States | ||
Early-stage technology investments are targeted by this venture capital firm. | innovationendeavors.com | Palo Alto, United States | ||
Horizons Ventures is focused on investing in deep science and technology. | horizonsventures.com | Hong Kong, China |
Investor details for Eikon
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Eikon
141 people are tracked at Eikon (73 in leadership, 8 in board & advisors, 60 in team); the tracked headcount is 431.
| Name | Role | Group |
|---|---|---|
Robert Tjian | Co-Founder | Leadership |
Luke Lavis | Co-Founder | Leadership |
Eric Betzig | Co-Founder | Leadership |
Roger M Perlmutter | CEO & President & Chairman | Leadership |
Xavier Darzacq | Founder | Leadership |
Rohit Malik | Senior Director Of Oncology And Immunology | Leadership |
Rajneesh Raina | Vice President Information Technology | Leadership |
Leah Cleary | Director | Leadership |
Brage Garofalo | Director Of Clinical Study Management, Clinical Operations | Leadership |
Paul Allegretti | Associate Director | Leadership |
Barbara Howes | Chief People Officer | Leadership |
Dan Anderson | Chief Scientific Officer | Leadership |
Xiang Wang | Sr. Director, Head Of Technical CMC | Leadership |
Olivia W. | Associate Director, Software Engineering | Leadership |
Brian Margolin | Associate Director, Microscopy | Leadership |
Roy Baynes | Chief Medical Officer | Leadership |
Carolyn Cho | Executive Director Clinical Pharmacology | Leadership |
Sujeet Pingale | Associate Director, Clinical Data Management | Leadership |
Roger Perlmutter | CEO | Leadership |
Surya Vangala | Senior Director, Clinical Study Management | Leadership |
121 more people are available in the full profile.
Complete people profiles for Eikon
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Eikon
Eikon is a publicly listed company on the NASDAQ with ticker symbol EIKN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date05 Feb 2026
- Listed onNASDAQ: EIKN
- Listed entityEikon Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS2825641036
- Share price$6.72 (-7.44% on the day) · 2026-10-13
- Market capitalisation$364.0M
- Volume (last session)406,924
Timeline of Eikon
5 dated milestones of Eikon across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Eikon is founded.
- Funding First funding round of $148.0M.
- Milestone Reaches Unicorn status.
- Funding Latest funding round, Series D, of $350.7M.
- IPO Lists on the stock exchange (IPO).
Competitors of Eikon
Eikon has 3 listed competitors in our database, 3 of them funded. They include Biogen, ADMA Biologics and Kymeratx.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| admabiologics.com | 2005 | Ramsey, United States | $17.55M | 498 | Plasma-based biologics are developed for immune deficiency and infectious diseases. | |
| kymeratx.com | 2016 | Cambridge, United States | $197M | 150 | Small molecule protein degraders are developed for various disorders. |
Detailed competitors of Eikon
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Eikon
The website of Eikon (eikontx.com) receives about 13.1K visits a month and ranks #3,245,561 among all websites worldwide, #4,259 in Biotechnology and Pharmaceuticals.
- Monthly visits13.1K
▲ 111.5% vs previous month
- Unique visitors3K
per month
- Global rank#3,245,561
among all websites
- Category rank#4,259
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit1.7
- Average visit1 min 27 sec
- DevicesDesktop 46% · Mobile 54%
Websites whose visitors overlap most with Eikon. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| curiaglobal.com | 100% | 29.7K | #736,785 | View details | |
| exelixis.com | 91% | 39.1K | #1,001,350 | View details | |
| biopharmadive.com | 80% | 680.7K | #208,628 | View details | |
| fiercebiotech.com | 64% | 858.3K | #81,022 | View details | |
| avirmax.com | 25% | View details |
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Eikon (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Eikon
Complete news archive for Eikon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eikon
Eikon was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Eikon is headquartered in Hayward, United States. It is registered at Hayward, California, United States.
Roger M Perlmutter is the CEO of Eikon, as recorded in our data.
Eikon is a funded company, having raised a total of $1.16B across 4 funding rounds to date. The company's 1st funding round was a Series A of $148M, raised on May 2021.
Eikon has 431 employees.
Eikon was founded in 2019 and is headquartered in Hayward, United States. The company operates in the biotechnology sector, focusing on drug discovery through a therapeutic platform. Protein dynamics are analyzed by researchers using live-cell super-resolution microscopy integrated with computing and engineering technologies. This approach supports the identification and evaluation of potential drug targets.
Eikon's top competitors include ADMA Biologics, Kymeratx and Biogen.
Eikon offers Therapeutic Platform, Pipeline, and Eikon Systems.
Yes, Eikon is publicly traded on NASDAQ under the ticker symbol EIKN.
Eikon has 24 investors. Key investors include ARE, T. Rowe Price, StepStone Group, Schroders, and CPP Investments.
The valuation of Eikon is $908.2M as of Feb 2026.